THE ENGOT-OV26/PRIMA PHASE 3 TRIAL: NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER WHO RESPONDED TO FRONT-LINE PLATINUM-BASED THERAPY

A randomized, double-blind phaseIII trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.03.231 ◽

2017 ◽

Vol 145 ◽

pp. 98

Author(s):

A. Gonzalez ◽

K.N. Moore ◽

M.R. Mirza ◽

I.B. Vergote ◽

B. Pothuri ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Advanced Ovarian Cancer ◽

Front Line ◽

Double Blind ◽

Platinum Based Chemotherapy

Get full-text (via PubEx)

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps5606 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS5606-TPS5606 ◽

Cited By ~ 4

Author(s):

Antonio Gonzalez-Martin ◽

Floor Jennishens Backes ◽

Klaus H. Baumann ◽

Dana Meredith Chase ◽

Mathias Konrad Fehr ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Front Line ◽

Double Blind ◽

Phase Iii Trial ◽

Platinum Based Chemotherapy

Get full-text (via PubEx)

A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdx372.057 ◽

2017 ◽

Vol 28 ◽

pp. v351 ◽

Cited By ~ 1

Author(s):

A. Gonzalez Martin ◽

L.A. Rojas ◽

P.S. Braly ◽

J. Barter ◽

D.M. O'Malley ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Advanced Ovarian Cancer ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicenter Phase

Get full-text (via PubEx)

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Case Medical Research ◽

10.31525/ct1-nct04169997 ◽

2019 ◽

Author(s):

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Advanced Ovarian Cancer ◽

First Line ◽

Line Chemotherapy

Get full-text (via PubEx)

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Case Medical Research ◽

10.31525/ct1-nct04229615 ◽

2020 ◽

Author(s):

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Advanced Ovarian Cancer ◽

First Line ◽

Platinum Based Chemotherapy

Get full-text (via PubEx)

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Randomised Controlled

Get full-text (via PubEx)

Faculty Opinions recommendation of Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717976556.793472766 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

International Collaboration ◽

Ovarian Neoplasms ◽

Randomised Trial ◽

Advanced Ovarian Cancer ◽

Life Outcomes ◽

Standard Chemotherapy ◽

Phase 3

Get full-text (via PubEx)

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61157-0 ◽

2009 ◽

Vol 374 (9698) ◽

pp. 1331-1338 ◽

Cited By ~ 494

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Fumiaki Takahashi ◽

Seiji Isonishi ◽

Toshiko Jobo ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Randomised Controlled

Get full-text (via PubEx)

The Current Funding Landscape of Bevacizumab (Avastin) As Front-Line Treatment for Advanced Ovarian Cancer: A Health Economics Dilemma

American Journal of Biomedical Science & Research ◽

10.34297/ajbsr.2021.12.001752 ◽

2021 ◽

Vol 12 (3) ◽

pp. 260-263

Author(s):

Shiru Liu

Keyword(s):

Ovarian Cancer ◽

Health Economics ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

Front Line

Get full-text (via PubEx)

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00531-3 ◽

2021 ◽

Author(s):

Susana Banerjee ◽

Kathleen N Moore ◽

Nicoletta Colombo ◽

Giovanni Scambia ◽

Byoung-Gie Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Brca Mutation ◽

Advanced Ovarian Cancer ◽

Newly Diagnosed ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)